AstraZeneca PLC (AZN)vsBright Minds Biosciences Inc (DRUG)
AZN
AstraZeneca PLC
$183.02
+1.10%
HEALTHCARE · Cap: $284.30B
DRUG
Bright Minds Biosciences Inc
$69.00
-7.38%
HEALTHCARE · Cap: $583.72M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
DRUG
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$183.02
$11.55 discount
Intrinsic value data unavailable for DRUG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : DRUG
The strongest argument for DRUG centers on Debt/Equity, Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : DRUG
The primary concerns for DRUG are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while DRUG is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Bright Minds Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Bright Minds Biosciences Inc. (DRUG) is a pioneering clinical-stage biotechnology company dedicated to creating innovative therapies for central nervous system disorders, with a strong focus on mental health and pain management. Harnessing its proprietary drug development platform, Bright Minds is advancing a diverse pipeline of treatments, strategically aligned with the growing acceptance of psychedelic therapies. The company's experienced management team and extensive intellectual property portfolio position it uniquely to capitalize on the surging demand for novel mental health solutions, representing a compelling investment opportunity for institutional investors in the dynamic pharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?